med fusion, an integrated molecular center of excellence and clinical trials service organization, and GenomOncology, a genomics technology and services provider, have announced a partnership to optimize treatment strategies based on the patient's disease state and tumor profile. The companies believe that GenomOncology's proprietary technology platform, the GO Clinical Workbench, and support services will complement med fusion's expanded solid tumor disease-specific panels and deliver a comprehensive laboratory report detailing relevant drug and clinical trial options.
med fusion's solid tumor menu expansion is anticipated early Q3 2014 with the launch of disease-specific panels including NSCLC (non small cell lung cancer) and CRC (colorectal cancer). The expanded oncology menu is powered in part by next generation sequencing (NGS) technology that med fusion validated in the summer of 2014 in its CLIA- and CAP-accredited laboratory.
According to company representatives, GenomOncology's GO Clinical Workbench streamlines the use of NGS data in conjunction with other analytic modalities, simplifies the creation of a summary report, and provides a fully traceable workflow and rules-based decision support for the clinical interpretation of genomic data. The platform is configured to each clinical laboratory's specific needs with systems integration, setting of quality control and annotation parameters, and design of the resultant clinical report.
“Cancer is a complex disease of the genome where each tumor has its own set of genetic alterations,” comments Dr. Tom Lohmann, CMO, med fusion. “Increased understanding of the underlying genetic changes that may be driving tumor growth or metastasis can enable precise treatment strategies tailored to the genetic profile of each patient's cancer.” Learn more about GO Clinical Workbench.Read more